Filings · News reference
-SEC Filing
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar
Analysts changed outlook on top names. Piper Sandler raises Mercury Systems' target price, Ascendiant Capital boosts Alzamend Neuro's target price, BTIG raises Henry Schein's target price, Cantor Fitzgerald increases Palo Alto's target price, Morgan Stanley cuts Baidu's target price, Cantor Fitzgerald slashes Crowdstrike Holdings' target price, Baird raises Donaldson Company's target price, B of A Securities cuts Pony AI's target price.
Ascendiant Capital analyst Edward Woo maintains Alzamend Neuro (NASDAQ:ALZN) with a Buy and raises the price target from $25 to $26.